Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2 − metastatic breast cancer

ConclusionOur results indicate that dose reduction of ribociclib is safe and do not compromise the efficacy of the treatment. Furthermore, the study supports translation of results from the MONALEESA trials to patients treated in real-world clinical settings.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research